Gangliosides As Siglec Ligands

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 2023 Jan 26

PMID 36701102

Authors

Ronald L Schnaar

Affiliations

Soon will be listed here.

Abstract

The structure of a sialoglycan can be translated into to a biological response when it binds to a specific endogenous lectin. Among endogenous sialic acid-binding lectins in humans are those comprising the 15-member Siglec family, most of which are expressed on overlapping sets of immune cells. Endogenous Siglec ligands are sialoglycolipids (gangliosides) and/or sialoglycoproteins, on cell surfaces or in the extracellular milieu, that bind to and initiate signaling by cell surface Siglecs. In the nervous system, where gangliosides are the predominant sialoglycans, Siglec-4 (myelin-associated glycoprotein) on myelinating cells binds to gangliosides GD1a and GT1b on nerve cell axons to ensure stable and productive axon-myelin interactions. In the immune system, Siglec-7 on natural killer cells binds to gangliosides GD3 and GD2 to inhibit immune signaling. Expression of GD3 and GD2 on cancer cells can lead to tumor immune evasion. Siglec-1 (sialoadhesin, CD169) on macrophages binds to gangliosides on tumors and enveloped viruses. This may enhance antigen presentation in some cases, or increase viral distribution in others. Several other Siglecs bind to gangliosides in vitro, the biological significance of which has yet to be fully established. Gangliosides, which are found on all human cells and tissues in cell-specific distributions, are functional Siglec ligands with varied roles driving Siglec-mediated signaling.

Citing Articles

Linking glycosphingolipid metabolism to disease-related changes in the plasma membrane proteome.

Monkhouse H, Deane J Biochem Soc Trans. 2024; 52(6):2477-2486.

PMID: 39641585 PMC: 11668283. DOI: 10.1042/BST20240315.

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.

Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec-7 and Siglec-9.

Adak A, Tseng H, Chang S, Chiang Y, Lyu K, Lee Y Adv Sci (Weinh). 2024; 12(2):e2412815.

PMID: 39555730 PMC: 11727393. DOI: 10.1002/advs.202412815.

Lectin-Based Approaches to Analyze the Role of Glycans and Their Clinical Application in Disease.

Ideo H, Tsuchida A, Takada Y Int J Mol Sci. 2024; 25(18).

PMID: 39337716 PMC: 11432504. DOI: 10.3390/ijms251810231.

Enzymatic Synthesis of Disialyllacto-N-Tetraose (DSLNT) and Related Human Milk Oligosaccharides Reveals Broad Siglec Recognition of the Atypical Neu5Acα2-6GlcNAc Motif.

Bao S, Shen T, Shabahang M, Bai G, Li L Angew Chem Int Ed Engl. 2024; 63(51):e202411863.

PMID: 39223086 PMC: 11631665. DOI: 10.1002/anie.202411863.

References

Daly J, Carlsten M, ODwyer M . Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer. Front Immunol. 2019; 10:1047. PMC: 6521797. DOI: 10.3389/fimmu.2019.01047. View

Attrill H, Takazawa H, Witt S, Kelm S, Isecke R, Brossmer R . The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem J. 2006; 397(2):271-8. PMC: 1513286. DOI: 10.1042/BJ20060103. View

Schauer R, Kamerling J . Exploration of the Sialic Acid World. Adv Carbohydr Chem Biochem. 2018; 75:1-213. PMC: 7112061. DOI: 10.1016/bs.accb.2018.09.001. View

Theruvath J, Menard M, Smith B, Linde M, Coles G, Dalton G . Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat Med. 2022; 28(2):333-344. PMC: 9098186. DOI: 10.1038/s41591-021-01625-x. View

Yang L, Zeller C, Shaper N, Kiso M, Hasegawa A, Shapiro R . Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc Natl Acad Sci U S A. 1996; 93(2):814-8. PMC: 40139. DOI: 10.1073/pnas.93.2.814. View

Pronker M, Lemstra S, Snijder J, Heck A, Thies-Weesie D, Pasterkamp R . Structural basis of myelin-associated glycoprotein adhesion and signalling. Nat Commun. 2016; 7:13584. PMC: 5150538. DOI: 10.1038/ncomms13584. View

Kasprowicz A, Sophie G, Lagadec C, Delannoy P . Role of GD3 Synthase ST8Sia I in Cancers. Cancers (Basel). 2022; 14(5). PMC: 8909605. DOI: 10.3390/cancers14051299. View

Ledeen R, Kopitz J, Abad-Rodriguez J, Gabius H . Glycan Chains of Gangliosides: Functional Ligands for Tissue Lectins (Siglecs/Galectins). Prog Mol Biol Transl Sci. 2018; 156:289-324. DOI: 10.1016/bs.pmbts.2017.12.004. View

von Itzstein M . The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007; 6(12):967-74. DOI: 10.1038/nrd2400. View

10.

Yu H, Gonzalez-Gil A, Wei Y, Fernandes S, Porell R, Vajn K . Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology. 2017; 27(7):657-668. PMC: 5458540. DOI: 10.1093/glycob/cwx026. View

11.

Siddiqui S, Vaill M, Do R, Khan N, Verhagen A, Zhang W . Human-specific polymorphic pseudogenization of protects against advanced cancer progression. FASEB Bioadv. 2021; 3(2):69-82. PMC: 7876704. DOI: 10.1096/fba.2020-00092. View

12.

Furukawa K, Hamamura K, Nakashima H, Furukawa K . Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas. Proteomics. 2008; 8(16):3312-6. DOI: 10.1002/pmic.200800228. View

13.

COLLINS B, Kiso M, Hasegawa A, Tropak M, Roder J, Crocker P . Binding specificities of the sialoadhesin family of I-type lectins. Sialic acid linkage and substructure requirements for binding of myelin-associated glycoprotein, Schwann cell myelin protein, and sialoadhesin. J Biol Chem. 1997; 272(27):16889-95. DOI: 10.1074/jbc.272.27.16889. View

14.

Varki A, Cummings R, Aebi M, Packer N, Seeberger P, Esko J . Symbol Nomenclature for Graphical Representations of Glycans. Glycobiology. 2015; 25(12):1323-4. PMC: 4643639. DOI: 10.1093/glycob/cwv091. View

15.

Yamakawa N, Yasuda Y, Yoshimura A, Goshima A, Crocker P, Vergoten G . Discovery of a new sialic acid binding region that regulates Siglec-7. Sci Rep. 2020; 10(1):8647. PMC: 7250851. DOI: 10.1038/s41598-020-64887-4. View

16.

Quarles R . Myelin-associated glycoprotein (MAG): past, present and beyond. J Neurochem. 2007; 100(6):1431-48. DOI: 10.1111/j.1471-4159.2006.04319.x. View

17.

Duan S, Paulson J . Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol. 2020; 38:365-395. DOI: 10.1146/annurev-immunol-102419-035900. View

18.

Schnaar R, Gerardy-Schahn R, Hildebrandt H . Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev. 2014; 94(2):461-518. PMC: 4044301. DOI: 10.1152/physrev.00033.2013. View

19.

Rapoport E, Mikhalyov I, Zhang J, Crocker P, Bovin N . Ganglioside binding pattern of CD33-related siglecs. Bioorg Med Chem Lett. 2003; 13(4):675-8. DOI: 10.1016/s0960-894x(02)00998-8. View

20.

Li T, Schnaar R . Congenital Disorders of Ganglioside Biosynthesis. Prog Mol Biol Transl Sci. 2018; 156:63-82. DOI: 10.1016/bs.pmbts.2018.01.001. View